Premium
Letter: questions regarding the diagnostic performance of serum assays for atrophic gastritis—Authors' reply
Author(s) -
Zagari R. M.,
Greenwood D. C.
Publication year - 2017
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.14369
Subject(s) - medicine , atrophic gastritis , gastritis , gastroenterology , dermatology , stomach
diagnosis and prevention in subjects with Helicobacter pylori-related chronic gastritis. In: Tonino P, ed. Gastritis and Gastric Cancer – New Insights in Gastroprotection, Diagnosis and Treatments. Rijeka: InTech; 2011:179-196. 4. Kawai T, Miki K, Ichinose M, et al. Changes in evaluation of the pepsinogen test result following Helicobacter pylori eradication therapy in Japan. Inflammopharmacology. 2007;15:31-35. 5. Urita Y, Hike K, Torii N, et al. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci. 2004;49:795-801. 6. Leja M, Camargo MC, Polaka I, et al. Detection of gastric atrophy by circulating pepsinogens: a comparison of three assays. Helicobacter. 2017;22:e016999.